VaxGen Inc. did not receive the results it and so many others hoped for after releasing Phase III trial data for its experimental AIDS vaccine, resulting in an investment backlash against the company's stock. (BioWorld Today)
VaxGen Inc. did not receive the results it and so many others hoped for after releasing Phase III trial data for its experimental AIDS vaccine, resulting in an investment backlash against the company's stock. (BioWorld Today)
NPS Pharmaceuticals Inc. and Enzon Pharmaceuticals Inc. shook hands on a merger that would create a combined company valued at $1.6 billion, a deal in which NPS essentially is offering about $750 million in stock for Enzon. (BioWorld Today)
NPS Pharmaceuticals Inc. and Enzon Pharmaceuticals Inc. shook hands on a merger that would create a combined company valued at $1.6 billion, a deal in which NPS essentially is offering about $750 million in stock for Enzon. (BioWorld Today)
Sunesis Pharmaceuticals Inc. entered a multiyear research collaboration with Merck & Co. Inc. to discover oral therapeutics to treat Alzheimer's disease. (BioWorld Today)
Sunesis Pharmaceuticals Inc. entered a multiyear research collaboration with Merck & Co. Inc. to discover oral therapeutics to treat Alzheimer's disease. (BioWorld Today)
